Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2026-05-22 AGM Information
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Notice of AGM
AGM Information Classification · 82% confidence The document is an RNS announcement titled “Notice of AGM” for Novacyt S.A., providing details of the upcoming Annual General Meeting (date, time, location) and noting that an investor presentation will be made available at the meeting. This is not a proxy statement, voting results, dividend notice, or a financial report but rather an AGM notice/meeting materials announcement. According to our definitions, this belongs to AGM Information (AGM-R).
2026-05-22 English
Convocation à l'assemblée générale annuelle
AGM Information Classification · 85% confidence The document is a formal notice (“Convocation à l’Assemblée Générale Annuelle”) announcing the date, time, venue, and registration details for the company’s upcoming Annual General Meeting. It does not contain financial statements or voting results, nor is it proxy materials or a full annual report. This fits the definition of AGM Information (materials related to the AGM itself).
2026-05-22 French
Launch of Yourgene® Insight DPYD assay
Regulatory Filings Classification · 87% confidence The document is an RNS press release announcing the commercial launch of a new Yourgene® Insight DPYD assay product. It contains a product description, management commentary, and corporate background, with no financial results, regulatory filings, or shareholder votes. It is a general corporate announcement distributed via RNS, so it falls under the ‘Regulatory Filings’ (RNS) category.
2026-05-19 English
Lancement du test Yourgene® Insight DPYD
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new diagnostic test product by Novacyt S.A. It describes the product features, market context, regulatory environment, and includes quotes from the CEO. There is no financial data, no mention of financial results, no regulatory filings, no meeting materials, no voting results, no management changes, no legal proceedings, no capital or financing updates, and no other report types. The document is a corporate announcement about a product launch, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other categories.
2026-05-19 French
Directorate change
Board/Management Information Classification · 95% confidence The document is a press release announcing a change in the company's board of directors and senior management, specifically the stepping down of the Chief Scientific Officer and board member. It does not contain financial data, audit information, or detailed reports. The document is titled 'Directorate Change' and includes commentary from the CEO about the departing director. This fits the category of Board/Management Information (MANG). The document length is 6171 characters, which is sufficient for a detailed announcement but does not constitute a full report. Therefore, the appropriate classification is MANG with high confidence.
2026-05-07 English
Changement au sein de la composition du Conseil d’administration
Board/Management Information Classification · 100% confidence The document is a press release announcing a change in the composition of the Board of Directors of Novacyt S.A., specifically the resignation of Dr. Joanne Mason from her roles as scientific director and board member. It includes statements from the CEO and contact information for investor relations. There is no financial data, no mention of a report being attached or published, and no regulatory form references. The content clearly fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2026-05-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.